Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Glaxosmithkline Plc (GSK)

Glaxosmithkline Plc (GSK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 110,792,888
  • Shares Outstanding, K 2,494,212
  • Annual Sales, $ 41,140 M
  • Annual Income, $ 4,836 M
  • 60-Month Beta 0.70
  • Price/Sales 2.68
  • Price/Cash Flow 10.64
  • Price/Book 4.95

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.68
  • Number of Estimates 2
  • High Estimate 0.70
  • Low Estimate 0.66
  • Prior Year 0.79
  • Growth Rate Est. (year over year) -13.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.78 +5.94%
on 10/15/19
46.01 -3.80%
on 10/31/19
+2.08 (+4.93%)
since 10/11/19
3-Month
39.68 +11.54%
on 08/14/19
46.01 -3.80%
on 10/31/19
+3.79 (+9.36%)
since 08/09/19
52-Week
36.41 +21.56%
on 12/06/18
46.01 -3.80%
on 10/31/19
+2.96 (+7.17%)
since 11/09/18

Most Recent Stories

More News
Human Respiratory Syncytial Virus Market Scope, Research Methodology, Rising Demand, Industry Trends & Revenue Models | Major Keys: F. Hoffmann-La Roche Ltd., Merck & Co

According to a recently published report by Research Nester titled "delivers the detailed overview of the global human respiratory syncytial virus market in terms of market segmentation by product type,...

GILD : 64.64 (-1.13%)
GSK : 44.26 (-0.36%)
MRK : 83.28 (-0.37%)
TEVA : 9.33 (+0.32%)
VRX.TO : 30.80 (-3.33%)
Novartis' Generics Unit to Buy Aspen's Japanese Operations

Novartis (NVS) inks a deal to acquire the Japanese business of Aspen Global Incorporated.

MRK : 83.28 (-0.37%)
BMY : 58.15 (+0.22%)
NVS : 88.63 (+0.29%)
GSK : 44.26 (-0.36%)
Teva (TEVA) Q3 Earnings Miss, Stock Up on Guidance Increase

Teva Pharmaceutical (TEVA) misses earnings estimate but beats the same for sales. The company increases the lower end of its 2019 sales and earnings guidance. Shares rise.

AGN : 181.58 (+0.17%)
GSK : 44.26 (-0.36%)
MYL : 17.24 (-2.10%)
TEVA : 9.33 (+0.32%)
Angioedema Treatment Market to Set Remarkable Growth by 2025

HTF MI recently introduced new title on "Global Angioedema Treatment Market Insights, Forecast to 2025" from its database. The report provides study with in-depth overview, describing about the Product...

GSK : 44.26 (-0.36%)
MRK : 83.28 (-0.37%)
VRX.TO : 30.80 (-3.33%)
Angioedema Treatment Market to See Major Growth by 2025

HTF MI recently introduced new title on "Global Angioedema Treatment Market Insights, Forecast to 2025" from its database. The report provides study with in-depth overview, describing about the Product...

GSK : 44.26 (-0.36%)
MRK : 83.28 (-0.37%)
VRX.TO : 30.80 (-3.33%)
Emergent (EBS) Beat Earnings in Q3, Vaccines Drive Sales

Emergent (EBS) rides high on both earnings and revenues beat in the third quarter. ACAM2000 and Narcan drive revenues.

SNY : 45.86 (unch)
GSK : 44.26 (-0.36%)
EBS : 53.75 (-0.54%)
ANIK : 60.23 (+0.02%)
Global Nanotechnology and Nanomedicine Treatment Markets Could Reach $350 Billion by 2025

Researchers in nanomedicine are making some big-time advances according to reports in various industry journals. Nanomedicine, a relatively new but rapidly developing branch of nanotechnology (the study,...

CELGZ : 0.48 (unch)
NNVC : 2.03 (unch)
CNST : 34.38 (+11.23%)
AGEN : 3.90 (+9.24%)
GSK : 44.26 (-0.36%)
CELG : 109.57 (+0.03%)
Theravance (TBPH) Q3 Loss In Line, Revenues Lag Estimates

Theravance's (TBPH) third-quarter loss matches estimates while revenues miss the same in absence of product sales due to the sale of its only marketed drug Vibativ to Cumberland Pharmaceuticals.

GSK : 44.26 (-0.36%)
JNJ : 131.98 (-0.77%)
TBPH : 17.56 (-0.23%)
MYL : 17.24 (-2.10%)
Irritable Bowel Syndrome (IBS) Therapeutics Market Analysed by Business Growth, Development Factors and Future Trends by 2026

Ameco Research in its report titled, "," offers comprehensive insights and detailed research on the global Irritable Bowel Syndrome (IBS) Therapeutics market over the forecast period 2019 - 2026. The report...

ABT : 83.76 (+0.02%)
ALPMF : 16.8000 (-1.47%)
GSK : 44.26 (-0.36%)
IRWD : 11.11 (+0.82%)
NVS : 88.63 (+0.29%)
SCMP : 18.05 (+0.28%)
SGYP : 0.03 (-52.00%)
VRX.TO : 30.80 (-3.33%)
Agenus (AGEN) Q3 Earnings Beat Estimates, Revenues Up Y/Y

Agenus (AGEN) posts narrower-than-expected loss and beats sales estimates in the third quarter of 2019.

GSK : 44.26 (-0.36%)
ACOR : 2.19 (-6.41%)
AGEN : 3.90 (+9.24%)
GILD : 64.64 (-1.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More Share

Trade GSK with:

Business Summary

GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central...

See More

Key Turning Points

2nd Resistance Point 44.47
1st Resistance Point 44.36
Last Price 44.26
1st Support Level 44.07
2nd Support Level 43.89

See More

52-Week High 46.01
Last Price 44.26
Fibonacci 61.8% 42.34
Fibonacci 50% 41.21
Fibonacci 38.2% 40.08
52-Week Low 36.41

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar